Abstract: Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors of Formula (I).

Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides methods and compositions for reducing globotriaosylceramide (Gb3) accumulation and treating diseases, disorders or conditions associated with Gb3 accumulation based on inhibitors of phosphatidylinositol-4-phosphate adaptor-2 (FAPP2), including interfering oligonucleotides, for example, siRNAs, and small molecule compounds based inhibitors. The present invention is particularly useful in treating Fabry disease and other sphingolipidoses relating to sphingolipid metabolism, such as Gaucher's disease.

Abstract: The present invention provides a combined drug for an injectable depot formulation having a superior effect of preventing and/or treating polycystic kidney disease. More specifically, the present invention relates to a drug for preventing and/or treating polycystic kidney disease, which is an injectable depot formulation comprising a particle containing tolvaptan or a prodrug thereof and a somatostatin analogue. The present invention also relates to a method for preventing and/or treating polycystic kidney disease using the drug.

Abstract: The present invention relates to novel compounds of Formula (I): which act as 5HT2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.

Abstract: The use of orexin 1 receptor antagonists and/or orexin 2 receptor agonists thereof in the treatment of bone loss diseases is described. Such conditions include osteoporosis, rheumatoid arthritis and other bone wasting diseases.

Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.

Abstract: A composition for transdermal delivery of a progestin for progestin hormone therapy is disclosed. Also disclosed is a transdermal delivery device comprising the composition. For progestin-only hormone therapy, the composition contains an anti-oxidant and does not contain an estrogen. For therapy involving a progestin and an estrogen, the composition contains the progestin, the estrogen and an additional anti-oxidant. Methods of improving the stability of progestin-containing compositions comprising oxidative agents are also disclosed. The methods comprise including one or more anti-oxidants in the compositions.

Abstract: The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition.

Abstract: The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.

Abstract: Cerclage pessary containing progesterone homogeneously distributed in the pessary body providing a prolonged, sustained and continuous release for a period of at least 6 months, wherein the pessary consists of dimethylsiloxane elastomer with RTV (Room Temperature Vulcanization) mechanism, the progesterone amount is from 20% to 30% w/w, relative to pessary weight and the ratios of the polymers forming the matrix is from 6:1 to 14 1. The cerclage pessary is useful for the prevention of preterm birth. Progesterone diffuses through the polymer continuously, without altering the shape and integrity of the pessary, since the elastomer forming the polymeric matrix used herein is not biodegradable.

Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.

Abstract: The present invention provides for pharmaceutical preparations, devices, systems and methods for the treatment of otic diseases and conditions. In various embodiments, the preparations, devices, systems and methods enable sustained drug release for the treatment or prevention of hearing loss, infections, and other pathological conditions of cochlea and inner ear.

Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.

Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.

Abstract: The present invention is a method of treating endometrial tissue disease and in particular a method of treating endometriosis and adenomyosis by administering an Epithelial-to-mesenchymal transition altering compound. The compound may be a natural compound or a synthetic compound. The compound may be in pill form, liquid form, or suppository form.

Abstract: Calcium glycerophosphate is found to be effective in treating and preventing a disease, disorder and/or condition of the respiratory system. The disease, disorder and/or condition is related to an obstructive or a restrictive condition of the respiratory airway.

Abstract: CYP2W1 levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of a hypoxia-activated achiral phosphoramidate mustards.

Abstract: The invention provides compounds and methods for inhibiting proteases. One aspect of the invention features pro-soft inhibitors which react with an activating protease to release an active inhibitor moiety in proximity to a target protease. In certain instances, compounds inhibit proteasomes and/or post-proline cleaving enzymes (PPCE), such as dipeptidyl peptidase IV. The compounds of the invention provide a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease.

Abstract: The present invention provides a method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis in a patient in need thereof, which comprises administering an effective amount of [(1R)-1-({[(2, 5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl] boronic acid or a citric acid ester thereof, or a pharmaceutically acceptable salt thereof to the patient.

Abstract: The present invention relates to a feed supplement and a feed containing this feed supplement, comprising 1) a homotrimer, heterotrimer, homotetramer and/or heterotetramer of a carbohydrate component selected from the group consisting of a pentose saccharide, a hexose saccharide, glucuronic and galacturonic acid, and 2) a medium-chain fatty acid (MCFA), selected from the group consisting of caproic acid (C6), caprylic (C8), capric (C10) and lauric acid (C12). The invention also refers to the use of the feed supplement or feed in order to improve the efficiency of animal production, such as weight gain, feed conversion, nutritive value, health and wellbeing through the selective elimination of enteropathogens.

Abstract: The present invention relates to a method of inhibiting growth of a cancerous cell. The method includes the step of exposing the cancerous cell to an anti-cancer therapy and an effective amount of a steroid saponin.

Abstract: Compositions containing nicotinamide riboside (NR) are provided. NR containing compositions are used in the care or treatment of skin and skin conditions. In some embodiments, the invention relates to pharmaceutical compositions and cosmetic compositions containing nicotinamide riboside. In further embodiments, the invention relates to methods of using nicotinamide riboside to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival. A method of treating signs or symptoms of aging or skin wrinkles in an individual is provided, comprising topically administering to the individual in need of such treatment an effective amount of the compound nicotinamide riboside, or salts thereof.

Abstract: Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The compounds are formulated with agents that enhance the oral delivery of the hypersulfated disaccharides. The delivery agents are selected from the group consisting of natural or synthetic polymers having ionic side chains as well as other compounds or types of compounds that improve the bioavailability of the disaccharides relative to delivery of the drug without such agents. The hypersulfated disaccharides are made from heparin or salts thereof.

Abstract: The present application relates to use of icaritin in preparing a medicament for preventing or treating hematocytopenia. Particularly, icaritin may be used to prevent or treat bone marrow suppression caused by chemotherapeutic drugs, and may also be used to prevent or treat thrombocytopenia, for example, immune thrombocytopenia.

Abstract: The present invention further relates to ivermectin, most preferably formulated as an implant for administration of pet and domestic animals. These formulations provide long term protection against Dirofilaria parasites, without the risks for secondary adverse events of conventional formulations. Preferred formulations are implants and are administered at least twice a year, once a year, or at least once in 18 months, up to 24 months.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of polyomavirus infections. In particular, the present invention relates to a method for treating a polyomavirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of gemcitabine.

Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of diffuse large B-cell lymphoma, follicular lymphoma, or mantel cell lymphoma, which comprises administering to a human having diffuse large B-cell lymphoma, follicular lymphoma, or mantel cell lymphoma a therapeutically effective amount of 5-azacytidine, or a pharmaceutically acceptable salt, solvate or hydrate thereof, and optionally administering therapeutically effective amounts of one or more additional active agents.

Abstract: Provided herein are compounds, compositions, and methods of using them to treat infections, neoplastic disease, inflammatory disease, and pain. Such compounds are nucleotides, acyclonucleotides, and ANP phosphonates conjugated with forms and/or moieties of Vitamin B6 for delivery past the cell membrane and into the cell.

Abstract: Methods and composition for potentiating germinal centers are disclosed herein. The methods include potentiating germinal centers to enhance antibody production in response to a vaccine, to increase antibody titer in response to a vaccine, and to enhance B cell class switching.

Abstract: The present invention provides novel methods for the modulation of autophagy and the treatment of autophagy-related diseases, including cancer, neurodegenerative diseases, liver diseases, muscle diseases and pancreatitis.

Abstract: Provided are therapeutic formulations and methods of use thereof.

Abstract: A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.

Abstract: Echogenic liposomes (ELIP) formulated with an at least partially pegylated phospholipid bi-layer shell, encapsulated nitric oxide, and encapsulated perfluorocarbon of the formula CxFy in a ratio of about 1:1 by volume, wherein X is greater than or equal to 3, are disclosed, along with methods for treating a patients suffering from cardiovascular disease by administering the ELIP at a site remote from the target diseased section, monitoring presence of the ELIP at the target diseased section, and administering ultrasound upon detection of presence such that bioactive NO is released at the target diseased section.

Abstract: Therapeutically-active compositions for treating pain, irritation, and inflammation associated with gastroesophageal reflux and Barrett's esophagus that combines at least one acid neutralizing strontium salt with at least one polyhydroxyphenol, at least one polymer, and optionally at least one cysteine based antioxidant.

Abstract: The invention provides for methods of treating a dialysis patient that is hyporesponsive to erythropoietin stimulating agents (ESA) comprising administering soluble ferric triphosphate (SFP) composition and administering a dose of ESA that is significantly reduced compared to the dose of ESA required by a dialysis patient that is hyporesponsive to ESA that has not received SFP.

Abstract: The present invention relates to methods of obtaining antigen-specific regulatory cells in vitro or in vivo. The regulatory cells are obtainable by inducing apoptosis of antigen-presenting cells by NKT cells. In particular, NKT cells are elicited, in vitro or in vivo, by exposure to CD1d-restricted NKT cell peptide epitopes either in natural configuration or modified as to contain a thioreductase motif within flanking residues. The present invention discloses methods to elicit immature antigen-presenting cells loaded with apoptotic cells or with apoptotic bodies for suppressing or preventing diseases such as autoimmune diseases, graft rejection and allergic diseases, and medicaments related thereto. Further disclosed are the use of antigen-specific regulatory cells for suppressing or preventing diseases such as autoimmune diseases, graft rejection and allergic diseases, and medicaments related thereto. Further disclosed are populations of antigen-specific regulatory cells obtained by this method.

Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.

Abstract: The present invention relates to a method of treating a subject having a disorder comprising administering to the subject an effective amount of a stem/progenitor cell isolated from the amniotic membrane of the umbilical cord or an effective amount of a cellular extract thereof.

Abstract: Hematopoeitic stem/progenitor cells (HSPC) and/or non-T effector cells are genetically modified to express (i) an extracellular component including a ligand binding domain that binds a cellular marker preferentially expressed on an unwanted cell; and (ii) an intracellular component comprising an effector domain. Among other uses, the modified cells can be administered to patients to target unwanted cancer cells without the need for immunological matching before administration.

Abstract: The invention is directed to a therapeutic composition that includes a first cell preparation that includes isolated stromal cells of a first type and a second cell preparation that includes isolated stromal cells of a second type. The first and second cell preparations may include cultured cells. The stromal cells may include adipose stromal cells and bone marrow derived stromal cells. The therapeutic composition may include a blood component that includes one or more of platelet-poor plasma, concentrated platelet-poor plasma, platelet-rich plasma, and whole blood.

Abstract: Compositions and methods are described herein for chemically inducing cells to change their differentiation state and become neuronal cells.

Abstract: Cardiac neural crest cells and methods for making and using the same to effect cardiac injury is described herein.

Abstract: Disclosed herein are methods for cryopreserving, hibernation and room temperature storage of PEC aggregates, implantable semipermeable devices and the VC combination product.

Abstract: The present invention relates to a method of preparing vascular endothelial cells by transforming (transdifferentiating) adult fibroblasts and a composition, which includes vascular endothelial cells prepared according to the method, for preventing and treating ischemic diseases, the method including a step of transducing adult fibroblasts with a gene. In particular, the present invention confirms that five factors, Foxo1, Er71, Klf2, Tal1, and Lmo2, induce transdifferentiation of adult fibroblasts into induced vascular endothelial cells. Furthermore, the present invention confirms that three factors, Er71, Klf2, and Tal1 induce transdifferentiation of human adult fibroblasts into induced vascular endothelial cells. The resultant induced endothelial cells enable lower limb salvaging by angiogenesis in lower limb ischemic animal models, showing that the induced endothelial cells can be effectively used for prevention or treatment of ischemic diseases.

Abstract: The present invention provides a method for treating an ocular disease in a subject in need thereof, comprising administering an effective amount of an extract of Taiwanese propolis (TP) or an active component thereof to the subject. Also provided is a pharmaceutical composition for treating an ocular disease, which comprises an effective amount of an extract of TP or an active component thereof, and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. For example, the present invention relates to compositions comprising non-replicating probiotic micro-organisms for use in the treatment of prevention of upper respiratory tract infections and/or their symptoms. Embodiments of the present invention can help parents to protect their children from such upper respiratory tract infections.

Abstract: The invention relates to compositions of purified filamentous bacteriophage, as well as methods that allow reproducible purification of high concentrations of filamentous bacteriophage.

Abstract: The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.

Abstract: There is a disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognising at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Coxsackie A-group viruses have been found to be particularly suitable. The cell adhesion molecule is desirably a member of the immunoglobulin (Ig) superfamily. Typically, the complement regulatory protein will be DAF.